Keros Therapeutics (KROS) Projected to Post Quarterly Earnings on Wednesday

Keros Therapeutics (NASDAQ:KROS) is anticipated to issue its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($0.49) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, February 27, 2026 at 4:00 PM ET.

Keros Therapeutics Price Performance

Keros Therapeutics stock opened at $16.52 on Wednesday. The company has a market cap of $503.36 million, a price-to-earnings ratio of 10.73 and a beta of 0.86. The firm has a 50-day moving average of $19.18 and a 200-day moving average of $17.04. Keros Therapeutics has a one year low of $9.12 and a one year high of $22.55.

Analysts Set New Price Targets

A number of research firms have weighed in on KROS. Bank of America raised their price target on Keros Therapeutics from $18.00 to $19.00 and gave the company a “neutral” rating in a research note on Friday, November 28th. Wedbush raised their target price on shares of Keros Therapeutics from $15.00 to $16.00 and gave the company a “neutral” rating in a research note on Thursday, November 6th. Oppenheimer reaffirmed an “outperform” rating and set a $27.00 price target (up from $23.00) on shares of Keros Therapeutics in a research report on Wednesday, November 12th. Wells Fargo & Company decreased their price objective on shares of Keros Therapeutics from $26.00 to $23.00 and set an “overweight” rating for the company in a research report on Tuesday, November 11th. Finally, TD Cowen upgraded shares of Keros Therapeutics to a “hold” rating in a research note on Friday, December 19th. Five investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Keros Therapeutics has an average rating of “Hold” and a consensus target price of $22.29.

Institutional Trading of Keros Therapeutics

Several large investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC boosted its stake in shares of Keros Therapeutics by 149.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after purchasing an additional 1,888 shares in the last quarter. New York State Common Retirement Fund boosted its position in Keros Therapeutics by 264.1% in the second quarter. New York State Common Retirement Fund now owns 10,616 shares of the company’s stock valued at $142,000 after buying an additional 7,700 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Keros Therapeutics by 8.6% during the second quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company’s stock worth $166,000 after buying an additional 988 shares during the last quarter. Sherbrooke Park Advisers LLC acquired a new position in shares of Keros Therapeutics during the third quarter worth $176,000. Finally, AQR Capital Management LLC bought a new position in shares of Keros Therapeutics in the 1st quarter valued at $226,000. 71.56% of the stock is owned by institutional investors and hedge funds.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.